Vaidya Sane Ayurved Laboratories Annual General Meeting
Vaidya Sane Ayurved Laboratories will hold its 27th Annual General Meeting on September 30, 2026, via video conferencing. The company also filed its FY 2025-26 Annual Report.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements
Vaidya Sane Ayurved Laboratories will hold its 27th Annual General Meeting on September 30, 2026, via video conferencing. The company also filed its FY 2025-26 Annual Report.
The company's board approved the 27th AGM details, director/auditor re-appointments, an increase in MD remuneration, and the introduction of the 'VSALL - ESOP 2026' scheme.
Vaidya Sane Ayurved Laboratories filed a statement of deviation or variation in fund utilization pursuant to Regulation 32(1) for the quarter ended June 30, 2026.
Vaidya Sane Ayurved Laboratories announced the resignation of Rohit Madhav Sane as CEO. Mr. D. Ramakrishna has been appointed as the new CEO and KMP.
The company clarified its earlier financial results submission to the NSE, addressing the missing balancing figure note and rectifying discrepancies in its Consolidated XBRL filing.
Vaidya Sane Ayurved Laboratories Ltd received Indian Patent No. 593487 for a herbal formulation method. The grant enhances its IP portfolio and supports its long‑term strategy.
Madhavbaug launched 'FoodRx', a clinically designed nutritional system for managing lifestyle disorders. The launch leverages data from 10 lakh patients to target diabetes and heart disease.
Madhavbaug reported FY26 revenue of ₹106.91cr (+18.89% YoY) and PAT of ₹8.99cr. The company is pivoting from wellness to higher-value disease reversal programs and expanding hospital capacity.
Vaidya Sane (Madhavbaug) reported FY26 enterprise revenue of ₹196.91 Cr, driven by a 320+ clinic network and 4 hospitals focusing on non-invasive cardiac care and disease reversal.
Vaidya Sane Ayurved Laboratories appointed new Secretarial and Internal Auditors. These appointments strengthen the company's regulatory compliance and internal governance frameworks.
Vaidya Sane Ayurved Laboratories Limited has scheduled a board meeting on May 15, 2026, to consider and approve its audited standalone and consolidated financial results for the year ended March 31, 2026. The company also confirmed that its trading window remains closed until May 17, 2026.
Vaidya Sane Ayurved Laboratories Limited clarified to the NSE that recent share price movements are purely market-driven. The company confirmed there is no undisclosed price-sensitive information or impending corporate actions. It remains in compliance with SEBI (LODR) Regulations and continues to promptly inform exchanges of all material events.
Vaidya Sane Ayurved Laboratories Limited informed the exchange regarding the non-applicability of Corporate Governance provisions under SEBI LODR Regulation 27. The company is exempted as it is listed on the NSE SME portal and meets the threshold criteria of having paid-up equity capital under ₹10 crore and net worth under ₹25 crore.
Vaidya Sane Ayurved Laboratories Limited informed the exchange regarding the non-applicability of the Annual Secretarial Compliance Report for FY2026. The company is exempted under SEBI Regulation 15(2) as its securities are listed on the SME Exchange. This filing confirms the company's compliance status with corporate governance provisions.
Vaidya Sane Ayurved Laboratories Limited (MADHAVBAUG) confirmed it does not fall under the 'Large Corporate' category for the financial year. This disclosure follows SEBI's framework for incremental borrowing by large entities. This routine regulatory update provides clarity on the company's borrowing classification.
Vaidya Sane Ayurved Laboratories Limited submitted an undertaking regarding the non-applicability of SEBI Corporate Governance regulations for the fiscal year ended March 31, 2026. As an SME-listed entity on the NSE, the company is exempted under Regulation 15 of SEBI (LODR) Regulations, 2015.
Vaidya Sane Ayurved Laboratories Limited's promoters have submitted their annual disclosure for the period ended March 31, 2026. The filing confirms that no encumbrance, direct or indirect, was created on the promoter group's shareholding during the year, maintaining a stable pledge-free ownership structure.